Articles By Rob Wright, Chief Editor

Biopharma’s Reputation — Out Of The Frying Pan And Into The Fire
Biopharma’s Reputation — Out Of The Frying Pan And Into The Fire Chief Editor Rob Wright discusses the implications of the recent Gallup poll indicating pharma presently being the most poorly regarded of all industries in the eyes of Americans.  Continue Reading...
  • The Opioid Addiction Crisis — A Historical View From The Front Lines
    The Opioid Addiction Crisis — A Historical View From The Front Lines

    Chief Editor Rob Wright saw glimpses into the impending opioid crisis back when he was working as a pharma sales rep in the pain management space.

  • The Story Of Pfizer’s R&D Turnaround
    The Story Of Pfizer’s R&D Turnaround

    Mikael Dolsten, M.D., Ph.D., CSO and president, worldwide research, development and medical (WRDM), reveals the decade long turnaround of the Pfizer’s R&D innovation engine leading to what could be the company’s best ever pipeline.

  • What’s Necessary To Realize The Promise Of Digital Health Solutions?
    What’s Necessary To Realize The Promise Of Digital Health Solutions?

    Representatives from the National Kidney Foundation, Bayer, and digital health startup up, Bitome, share their views on what’s necessary to realize the promise of innovative digital health solutions toward treating the whole patient during an educational panel session at the 2019 BIO International Convention And Conference.

  • Jeremy Levin Weighs In On Biosimilar Patent Thicket
    Jeremy Levin Weighs In On Biosimilar Patent Thicket

    At the 2019 BIO Conference Chief Editor Rob Wright sat down with newly elected board-director chair, Jeremy Levin, DPhil, MB, BChir, CEO of Ovid Therapeutics to talk patent thickets and his role with BIO.

  • Oh, The Misperceptions We Hold
    Oh, The Misperceptions We Hold

    I was fearful that the Pfizer executive I was set to interview would be overly coached and not be transparent regarding his experiences. But that wasn’t the case at all.

  • Is It Time To Throw In The Towel On Biosimilars In The U.S.?
    Is It Time To Throw In The Towel On Biosimilars In The U.S.?

    Rob Wright takes issue with Peter Bach, M.D., and Mark Trusheim’s recommendation that the U.S. would be better served by abandoning continued biosimilar drug development.

  • Think You Know About Extreme Teaming?
    Think You Know About Extreme Teaming?

    Rob Wright digs into the “extreme teaming” work of Amy Edmondson, Novartis professor of leadership and management at Harvard, and Jean-Francois Harvey, assistant professor at HEC Montreal, drawing on the 2010 Chilean mining disaster as an example.

  • Some Things Come From No Things
    Some Things Come From No Things

    Many of us have good or even great ideas for a business, product or service, but only a handful follow through. Why?

  • How Serial Entrepreneur Robert Hariri Is Revolutionizing Cell Therapy
    How Serial Entrepreneur Robert Hariri Is Revolutionizing Cell Therapy

    Robert Hariri, M.D., Ph.D., is an engineer, a jet aviator, a movie producer, a professor and a surgeon. However, it’s his experience as a biomedical scientist that led to him to be a successful serial entrepreneur, including his most recent biopharma venture — Celularity Therapeutics.

Rob Wright

Rob Wright



Rob Wright is the chief editor of Life Science Leader magazine. Prior to joining the publication, he spent nearly 20 years in the pharmaceutical industry. During his industry career, Wright conducted well over 1,000 presentations and roundtable discussions, including the facilitation of FDA-mandated clinical training programs for hundreds of licensed healthcare providers. He has chaired, moderated, and served as a speaker at industry and academic conferences, and served as co-chair for the 2015 and 2018 BIO International conference’s educational planning committee. Wright’s 500+ published articles have appeared in peer-reviewed academic journals, B2B magazines and online publications. He received a B.S. in Business Administration from Indiana University of Pennsylvania, MBA with distinction from Gannon University, and completed his doctoral coursework in marketing at Cleveland State University. He is a member of international business honor societies Sigma Beta Delta and Beta Gamma Sigma. He can be followed on Twitter @RfwrightLSL